



EMIF Deliverable 6.4: Use metabolomics to discover novel biomarkers

Executive summary

Executive Summary

We are measuring over 900 blood metabolites in a total of 6,000 individuals from the EPIC-Norfolk cohort study using an untargeted metabolomics platform (Metabolon Inc. - DiscoveryHD4® platform). The platform was chosen on the basis of an extensive options appraisal. Results are expected to become available in January 2016 and will be used to conduct Mendelian randomisation analyses of blood metabolites and risk of the metabolic complications of obesity.

Contacts

EMIF-Metabolic: Dawn Waterworth and Ulf Smith

Dawn.M.Waterworth@gsk.com / ulf.smith@medic.gu.se